The acquisition will add 20,000 litres of installed biologics drug substance manufacturing capacity for Syngene
Both the India and GCC entities will be operated by separate dedicated management teams
Emphasizes the need for a collective effort on bolstering resilience across economies, societies, healthcare systems, education systems and infrastructure
Lack of technology transfer stands out as a formidable barrier
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
Increased capability to produce medicines for challenging diseases including cancer
Dr. Singh proposes upskilling medicos with AI, Quantum and other newer technologies to meet the changing requirements of patient care
The Main campaign started from October 2
The extension builds upon an existing long-term collaboration for end-to-end ADC manufacturing, including payload, monoclonal antibody (mAb) manufacturing and bioconjugation
His M&A background and experience with successful private-equity-backed companies will benefit the company’s growth and diversification strategy
Subscribe To Our Newsletter & Stay Updated
